Breast Cancer Trials / Trials in Montana
20 Recruiting Trials

Clinical Trials
for Breast Cancer in Montana

20 clinical trials for Breast Cancer are currently recruiting participants at study sites in Montana. Study-related care is provided at no cost.

20
Recruiting trials
26
Study sites
9
Cities
7
Industry-sponsored
4
Phase 2
11
Phase 3

Breast Cancer clinical trials in Montana: what to expect

Breast cancer trials are sorted first by subtype, because the treatments differ: hormone-receptor-positive, HER2-positive (including the newer HER2-low group) and triple-negative disease each have their own studies. Most recruiting trials test a new drug or combination, including targeted pills, antibody-drug conjugates and immunotherapy, either for metastatic cancer or before and after surgery for early-stage disease. Others study less surgery or radiation, ways to reduce recurrence, and screening for people at higher risk.

In Montana, recruiting breast cancer studies are concentrated in Billings, Bozeman, Missoula and Great Falls, with sites in 5 other cities. 7 of the 20 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who breast cancer trials usually look for

Listings name the subtype, the stage (early or metastatic) and how many treatments you may already have had. Early-stage trials often enroll between diagnosis and surgery, or in the months after surgery; metastatic trials usually enroll when a treatment has stopped working. Some specify menopausal status or a particular mutation (BRCA, PIK3CA, ESR1), which the site can test for. Nearly all require that you are well enough for daily activity and that recent blood work is adequate.

Your receptor status is on your pathology report; the site will confirm it from that report, so you do not need to know it by heart to ask.

What taking part involves

Screening reviews your pathology and scans and adds blood work, sometimes a biopsy. Treatment then runs in cycles, with infusions every two to three weeks or daily pills, and scans every two to three months to check the response. Early-stage trials follow you for years after treatment ends, usually with a visit or call every few months. Study drugs and study-specific tests are free; care you would receive anyway is billed to insurance as usual. Placebo, when used, is added to standard treatment.

Questions worth asking the study team

How the study treatment compares with what your oncologist would otherwise recommend; whether the trial is randomized and what the other arm receives; what happens if the cancer grows or returns; and how visits fit around work and family. Many trials now allow some visits at a local clinic.

Showing 20 of 20 recruiting Breast Cancer trials in Montana

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
PHASE3 Jonesboro, Arkansas +4 sites NCT06757634
This trial is looking for adults with advanced breast cancer that is HR-positive and HER2-negative. Participants will receive treatment involving gedatolisib along with other medications.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
PHASE1 Hot Springs, Arkansas +4 sites NCT07310420
This trial is looking for premenopausal women aged 18 to 55 who have been diagnosed with early or advanced hormone receptor positive breast cancer. Participants will receive ZOLADEX to help assess ovarian suppression.
Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3 Birmingham, Alabama +4 sites NCT04852887
This trial is looking for women with early-stage hormone-sensitive breast cancer who are interested in taking part in a study on surgery and hormone therapy without radiation. Participants will need to meet specific health criteria to join.
Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
PHASE3 Jonesboro, Arkansas +4 sites NCT07391774
This trial is looking for women who are postmenopausal and have high stage breast cancer that is less likely to come back. Participants will compare hormone therapy and ribociclib to chemotherapy followed by hormone therapy and ribociclib.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3 Phoenix, Arizona +4 sites NCT06876714
This trial is looking for adults with HER2-positive breast cancer who have no residual invasive disease after chemotherapy. Participants will receive either 6 or 12 months of HER2-targeted medications to see which duration works best.
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3 Birmingham, Alabama +4 sites NCT05812807
This trial is looking for people with early-stage triple-negative breast cancer who had no cancer left after previous treatments. Participants will either continue receiving pembrolizumab or just be monitored after surgery to see which approach works better to prevent cancer from coming back.
Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05929768
This trial is looking for women with early-stage triple negative breast cancer. Participants will receive a shorter treatment plan involving chemotherapy and immunotherapy without a certain type of drug called anthracyclines.
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
PHASE2 Phoenix, Arizona +4 sites NCT07007559
This trial is looking for women with advanced HER2-positive breast cancer who have received previous treatment. Participants will take part in a study to see how well the drug evorpacept works when combined with trastuzumab and chemotherapy.
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NA Anchorage, Alaska +4 sites NCT03723928
This trial is looking for women with hormone receptor positive, HER2 negative metastatic breast cancer. Participants will be monitored using specific blood tests and imaging to check how well their cancer treatment is working.
Recruiting
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
PHASE2 Billings, Montana +4 sites NCT06797635
This trial is looking for women with early-stage breast cancer, specifically triple-negative or hormone receptor-low positive/HER2 negative. Participants will receive a combination of treatments before surgery to see how effective they are compared to another treatment group.
Recruiting
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
PHASE3 Anchorage, Alaska +4 sites NCT03418961
This trial is looking for patients with breast cancer that has spread to other parts of the body. Participants must be receiving trastuzumab-based treatment and will be monitored for potential heart problems.
Recruiting
Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
PHASE2 Missoula, Montana +1 sites NCT07001241
This trial is looking for rural cancer survivors experiencing fatigue related to their cancer. Participants will follow a 12-week exercise program remotely, with regular check-ins and assessments throughout the process.
Recruiting
Integrated Cancer Repository for Cancer Research
N/A Greenwood Village, Colorado +4 sites NCT02012699
This trial is looking for adults who have a history of cancer, are at risk for developing cancer, or are healthy individuals. Participants will provide consent and may help advance cancer research by sharing data and samples.
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
N/A Birmingham, Alabama +4 sites NCT03452774
This trial is looking for cancer patients to see if an AI tool can help match them to clinical trials. Patients will have their cancer-related biomarkers evaluated to find suitable studies for their condition.
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
PHASE2 Birmingham, Alabama +4 sites NCT05564377
This trial is looking for patients with advanced solid tumors that have either spread to nearby areas or other parts of the body and who have not improved with standard treatments. Participating involves having genetic testing and possibly a biopsy to help find a suitable treatment that targets specific genetic changes in the tumor.
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
N/A Anchorage, Alaska +4 sites NCT05334069
This trial is looking for people with and without cancer to collect blood samples. Participants will help researchers develop tests for early cancer detection.
Recruiting
See all 20 Breast Cancer trials in Montana

Where the Breast Cancer studies are in Montana

Research sites running the most studies
  • Billings Clinic Cancer Center, Billings11 trials
  • Bozeman Health Deaconess Hospital, Bozeman11 trials
  • Benefis Sletten Cancer Institute, Great Falls9 trials
  • Community Hospital of Anaconda, Anaconda9 trials
  • Community Medical Center, Missoula9 trials
  • Logan Health Medical Center, Kalispell7 trials
By city

Counts are recruiting studies listing at least one site in Montana, from ClinicalTrials.gov, refreshed every two days.

Breast Cancer clinical trials in Montana: common questions

How many Breast Cancer clinical trials are recruiting in Montana?
TrialFinder currently lists 20 recruiting Breast Cancer clinical trials with study sites in Montana. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Breast Cancer clinical trials located in Montana?
Study sites for the Breast Cancer trials listed on this page include Billings, Missoula. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Breast Cancer clinical trial in Montana?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Breast Cancer trials in Montana also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Breast Cancer clinical trial in Montana?
Each study sets its own criteria based on age, Breast Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Do I need to know my receptor status to join a breast cancer trial?
It helps, because trials are organized by subtype, but the study site reads it from your pathology report. If a trial needs a test you have not had, such as HER2-low or a BRCA result, the site arranges it.
Are there trials for early-stage breast cancer?
Yes. Early-stage trials enroll before surgery, after surgery, or during the years of hormone therapy that follow, and test ways to lower the chance the cancer returns. The listing says which window it enrolls in.
Will a trial replace the treatment my oncologist planned?
Sometimes it is the plan, with a new drug added or compared; sometimes it is an alternative to discuss. Bring the trial page to your oncologist, who can refer you to the site or advise on timing.
Breast Cancer Trials in Other States
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
Helpful Reading
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Breast Cancer trials near you in Montana.

Get Matched — Free
No insurance required
About Breast Cancer Trials

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Breast Cancer trials →
Other Conditions in Montana
Diabetes Cancer Depression Anxiety Alzheimer's Heart Disease Asthma Multiple Sclerosis Obesity Parkinson's Lupus Hypertension COPD Stroke Arthritis Kidney Disease COVID-19
All trials in Montana →